Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Dalton Transactions

• Publication date

  2015-01-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c4dt02710hPMID 25369773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ.

  2014cited by this paper
• A targeted theranostic platinum(IV) prodrug containing a luminogen with aggregation-induced emission (AIE) characteristics for in situ monitoring of drug activation.

  2014cited by this paper
• Identification of functional peptides from natural and synthetic products on their anticancer activities by tumor targeting.

  2014cited by this paper
• Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one.

  2014cited by this paper
• Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(IV) prodrugs

  2014cited by this paper
• Recent progress of ICP-MS in the development of metal-based drugs and diagnostic agents

  2014cited by this paper
• Targeted delivery of platinum-based anticancer complexes.

  2013cited by this paper
• Targeting and delivery of platinum-based anticancer drugs.

  2013cited by this paper
• Synthesis and Structure–Activity Relationship Study of Organometallic Bioconjugates of the Cyclic Octapeptide Octreotate

  2013cited by this paper
• Synthetic methods for the preparation of platinum anticancer complexes.

  2013cited by this paper
• Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.

  2013cited by this paper
• Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer

  2013cited by this paper
• Next-generation metal anticancer complexes: multitargeting via redox modulation.

  2013cited by this paper
• New technologies and their impact on 'omics' research.

  2013cited by this paper
• Molecular mechanisms of cisplatin resistance

  2012cited by this paper
• Synthesis and in vitro cytotoxicity of cis,cis,trans-diamminedichloridodisuccinatoplatinum(IV)-peptide bioconjugates.

  2012cited by this paper
• α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.

  2012cited by this paper
• Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.

  2012cited by this paper
• RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.

  2012cited by this paper
• Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.

  2012cited by this paper
• Redox activation of metal-based prodrugs as a strategy for drug delivery.

  2012cited by this paper
• What do we know about the reduction of Pt(IV) pro-drugs?

  2012cited by this paper
• Camptothecins in tumor homing via an RGD sequence mimetic.

  2012cited by this paper
• Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes.

  2012cited by this paper
• RAM, an RGDS Analog, Exerts Potent Anti-Melanoma Effects In Vitro and In Vivo

  2011cited by this paper
• Targeted delivery of a proapoptotic peptide to tumors in vivo

  2011cited by this paper
• Functionalization of osmium arene anticancer complexes with (poly)arginine: effect on cellular uptake, internalization, and cytotoxicity.

  2011cited by this paper
• Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex.

  2011cited by this paper
• Folate-targeted therapies for cancer.

  2010cited by this paper
• A potent trans-diimine platinum anticancer complex photoactivated by visible light.

  2010cited by this paper
• Application of click-click chemistry to the synthesis of new multivalent RGD conjugates.

  2010cited by this paper
• Integrins in cancer: biological implications and therapeutic opportunities

  2010cited by this paper
• RGD-cyclam conjugate: synthesis and potential application for positron emission tomography.

  2010cited by this paper
• Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides.

  2010cited by this paper
• Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.

  2010cited by this paper
• Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides

  2010cited by this paper
• The status of platinum anticancer drugs in the clinic and in clinical trials.

  2010cited by this paper
• One-pot approach to well-defined biomolecular assemblies by orthogonal chemoselective ligations.

  2009cited by this paper
• Clustering and Internalization of Integrin αvβ3 With a Tetrameric RGD-synthetic Peptide.

  2009cited by this paper
• Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.

  2009cited by this paper
• Targeted delivery of activatable fluorescent pro-apoptotic peptide into live cells.

  2009cited by this paper
• Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells.

  2009cited by this paper
• Peptides for tumour therapy and diagnosis: current status and future directions.

  2009cited by this paper
• RAFT Nano‐constructs: surfing to biological applications

  2008cited by this paper
• Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.

  2008cited by this paper
• In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.

  2008cited by this paper
• Resistance against novel anticancer metal compounds: differences and similarities.

  2008cited by this paper
• Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

  2008cited by this paper
• Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device.

  2008cited by this paper
• Basis for design and development of platinum(IV) anticancer complexes.

  2007cited by this paper
• In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• In vivo imaging of tumour angiogenesis in mice with the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD

  2007cited by this paper
• Platinum(IV) analogues of AMD473 (cis-[PtCl2(NH3)(2-picoline)]): preparative, structural, and electrochemical studies.

  2006cited by this paper
• Multivalent RGD synthetic peptides as potent αVβ3 integrin ligands

  2006cited by this paper
• Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.

  2006cited by this paper
• Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.

  2005cited by this paper
• Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

  2005cited by this paper
• Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS).

  2004cited by this paper
• Integrins and angiogenesis.

  2004cited by this paper
• Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes.

  2004cited by this paper
• Peptide receptors as molecular targets for cancer diagnosis and therapy.

  2003cited by this paper
• The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction.

  2002cited by this paper
• αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin

  2002cited by this paper
• Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides.

  2001cited by this paper
• Synthetic multivalent ligands in the exploration of cell-surface interactions.

  2000cited by this paper
• Induction of lung fibroblast apoptosis by soluble fibronectin peptides.

  2000cited by this paper
• N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists

  1999cited by this paper
• RGD peptides induce apoptosis by direct caspase-3 activation

  1999cited by this paper
• N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.

  1999cited by this paper
• Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.

  1998cited by this paper
• Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

  1998cited by this paper
• cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

  1997cited by this paper
• Definition of Two Angiogenic Pathways by Distinct αv Integrins

  1995cited by this paper
• Definition of two angiogenic pathways by distinct alpha v integrins.

  1995cited by this paper
• Integrin expression in human melanoma cells with differing invasive and metastatic properties

  1992cited by this paper
• Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

  1990cited by this paper

• Tetrahedral framework nucleic acids: Nanokeys unlocking a new Era of precision biomedicine.

  2025cites this paper
• Platinum‐Based Chemotherapeutics in the Modern Era: From Classical DNA‐Targeting Mechanisms to Next‐Generation Innovations in Cancer Therapy

  2025cites this paper
• Exploring the Structure–Activity Relationships of Albumin-Targeted Picoplatin-Based Platinum(IV) Prodrugs

  2025cites this paper
• Platinum(IV) Prodrug-Coupled TAT Nuclear-Targeting Peptide for Drug Delivery and High Antitumor Efficacy with Low Toxicity.

  2025cites this paper
• Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

  2024cites this paper
• Unlocking the potential of RGD-conjugated gold nanoparticles: a new frontier in targeted cancer therapy, imaging, and metastasis inhibition.

  2024cites this paper
• Advances in the Study of Bioactive Nanoparticles for the Treatment of HCC and Its Postoperative Residual Cancer

  2023cites this paper
• Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

  2023cites this paper
• Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs

  2022cites this paper
• Molecular Delivery of Cytotoxic Agents via Integrin Activation

  2021cites this paper
• Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?

  2021cites this paper
• Application of ICP-MS to the development of metal-based drugs and diagnostic agents: where do we stand?

  2021cites this paper
• Toxic Effect of Platinum Compounds: Molecular Mechanisms of Toxicity

  2021cites this paper
• Research progress of azido-containing Pt(IV) antitumor compounds.

  2021cites this paper
• Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds.

  2021cites this paper
• RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances

  2021cites this paper
• Reactive Pt(II) center as part of redox-active quinoline-based heterocyclic scaffolds toward new anticancer leads.

  2020cites this paper
• Unexpected photoactivation pathways in a folate-receptor-targeted trans-diazido Pt(iv) anticancer pro-drug.

  2020cites this paper
• Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.

  2020cites this paper
• Rational design of anticancer platinum(IV) prodrugs

  2020cites this paper
• Platinum(IV) antitumor complexes and their nano-drug delivery

  2020cites this paper
• A nucleus-directed bombesin derivative for targeted delivery of metallodrugs to cancer cells.

  2020cites this paper
• Prodrugs as drug delivery system in oncology

  2019cites this paper
• Photoactive platinum(iv) complex conjugated to a cancer-cell-targeting cyclic peptide.

  2019cites this paper
• A view on multi-action Pt(IV) antitumor prodrugs

  2019cites this paper
• Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides.

  2019cites this paper
• Prodrugs activated by implantable microsystems

  2019cites this paper
• Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.

  2019cites this paper
• Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

  2019cites this paper
• Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.

  2019cites this paper
• Mechanism of Action of Anticancer Metallodrugs

  2018cites this paper
• Development of an Efficient Dual‐Action GST‐Inhibiting Anticancer Platinum(IV) Prodrug

  2018cites this paper
• Synthesis and Characterization of Nitric Oxide-Releasing Platinum(IV) Prodrug and Polymeric Micelle Triggered by Light.

  2018cites this paper
• Rational Design of Cancer-Targeted Selenadiazole Derivative as Efficient Radiosensitizer for Precise Cancer Therapy.

  2018cites this paper
• Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides

  2018cites this paper
• Cancer-targeted delivery systems based on peptides.

  2018cites this paper
• Stimuli-Responsive Therapeutic Metallodrugs.

  2018cites this paper
• Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands

  2018cites this paper
• Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.

  2018cites this paper
• Biomedical applications of functional peptides in nano-systems

  2018cites this paper
• Pt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents

  2017cites this paper
• Multi-Targeted Anticancer Agents.

  2017cites this paper
• Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.

  2017cites this paper
• Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

  2017cites this paper
• Synthesis and Biological Evaluation of Ru(II) and Pt(II) Complexes Bearing Carboxyl Groups as Potential Anticancer Targeted Drugs.

  2017cites this paper
• A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research.

  2017cites this paper
• May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs?

  2017cites this paper
• RGD-mediated delivery of small-molecule drugs.

  2017cites this paper
• Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides

  2017cites this paper
• Synthesis and biological evaluation of a Platinum(II)-c(RGDyK) conjugate for integrin-targeted photodynamic therapy.

  2017cites this paper
• Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe3O4 composite as a novel nanoscale molecular probe for early diagnosis and therapy in hepatocellular carcinoma

  2017cites this paper
• Efficient siRNA-peptide conjugation for specific targeted delivery into tumor cells.

  2017cites this paper
• Multifunctional αvβ6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting.

  2017cites this paper
• Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer

  2016cites this paper
• Synthesis, characterization, and anticancer activities of lipophilic pyridinecarboxaldimine platinum(II) complexes

  2016cites this paper
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

  2016cites this paper
• Small Molecules for Active Targeting in Cancer

  2016cites this paper
• The Platin-X series: activation, targeting, and delivery.

  2016cites this paper
• Advancement in integrin facilitated drug delivery.

  2016cites this paper
• A Green Light-Triggerable RGD Peptide for Photocontrolled Targeted Drug Delivery: Synthesis and Photolysis Studies.

  2016cites this paper
• Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications.

  2016cites this paper
• Dual-function fluorescent probe for cancer imaging and therapy.

  2016cites this paper
• A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy.

  2016cites this paper
• Platinum(iv) anticancer prodrugs - hypotheses and facts.

  2016cites this paper
• The state-of-play and future of platinum drugs.

  2015cites this paper
• An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies.

  2015cites this paper
• Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

  2015cites this paper
• Drug delivery and release systems for targeted tumor therapy

  2015cites this paper
• Platinum anticancer drugs and drug delivery systems

  2015influential citation
• A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin.

  2015cites this paper